US Stock MarketDetailed Quotes

VALN Valneva

Watchlist
  • 5.750
  • +0.100+1.77%
Close Nov 1 16:00 ET
  • 5.750
  • 0.0000.00%
Post 20:01 ET
466.55MMarket Cap-11015P/E (TTM)

About Valneva Company

Valneva SE is a specialty vaccine company, which focuses on the development, manufacturing, and commercialization of prophylactic vaccines for infectious diseases. It operates through the following segments: Commercialized Products, COVID, Vaccine Candidates, and Technologies and Services. The Commercialized Products segment markets vaccines, currently IXIARO and DUKORAL vaccines, as well as third-party products. The COVID segment develops, manufactures, and distribute related to COVID-19 vaccine candidate, VLA2001. The Vaccine Candidates segment focuses on proprietary research and development programs aiming to generate new approvable products to generate future cash flows from product sales or from commercialization through partnering with pharmaceutical companies. The Technologies and Services segment offers services and inventions at a commercialization stage. The company was founded on April 7, 1999 and is headquartered in Saint-Herblain, France.

Company Profile

SymbolVALN
Company NameValneva
Issue Price26.41
Founded1999
CEOMr. Thomas Lingelbach
MarketNASDAQ
Employees676
Securities TypeDR
ADS Ratio1.0 : 2.0
Fiscal Year Ends12-31
AddressCampus Bio-Ouest,6, rue Alain Bombard
CitySaint-Herblain
ProvinceGE
CountryFrance
Zip Code44800
Phone33-2-28-07-37-10

Company Executives

  • Name
  • Position
  • Salary
  • Thomas Lingelbach
  • Director, President and Chief Executive Officer
  • 401.34K
  • Petra Pesendorfer
  • Chief People Officer
  • --
  • Vincent Dequenne
  • Chief Operating Officer
  • --
  • Peter Buhler
  • Chief Financial Officer
  • 558.83K
  • Franck Grimaud
  • Chief Business Officer
  • 401.34K
  • Dr. Juan Carlos Jaramillo, M.D.
  • Chief Medical Officer
  • 539.76K
  • Dipal Patel
  • Chief Commercial Officer
  • 516.75K
  • Anne-Marie Graffin
  • Chairman of the Board
  • 74.30K
  • James R. Sulat
  • Vice Chairman of the Board
  • 74.07K
  • Dr. Kathrin Jansen
  • Director
  • 28.25K
  • James Connolly
  • Independent Director
  • 66.11K
  • Mailys Ferrere
  • Independent Director
  • --
  • Frederic Jacotot
  • General Counsel and Corporate Secretary
  • 305.20K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data